← 返回前沿论文

CRC 中 SH3BP2 基因组改变与表达谱的计算机模拟分析

英文原题:In silico analysis of SH3BP2 genomic alterations and expression profiles in CRC.

查看英文原题

In silico analysis of SH3BP2 genomic alterations and expression profiles in CRC.

PubMed 2026/09/02(内容时间) Per Med Q4 · IF 1.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究思路按摘要原文分段

结直肠癌(CRC)是一个广泛存在的健康问题,死亡率高。接头蛋白SH3BP2扩增会导致代谢改变、氧化应激、NK细胞活性和炎症。NK细胞无需预先激活即可摧毁肿瘤细胞,有助于防止转移,并具有预后价值。靶向SH3BP2以调节TME中NK细胞活性,可增强基于CRC的免疫治疗。

癌症标志工具有助于理解SH3BP2标志注释。利用STRING工具和KEGG通路,分析了蛋白质功能富集和PPI网络。使用TIMER 2.0进行免疫细胞浸润相关性分析,使用UALCAN进行基于CPTAC的蛋白质表达谱分析。结果与结论:GEO(GSE9348)数据集显示SH3BP2在CRC中上调(log2 fold change = 1.18)。GEO、TCGA和cBioPortal揭示了CRC病例中SH3BP2的改变,可能有助于免疫逃逸。SH3BP2中的突变影响癌症生长,通过激活NF- B并经由WNT/ -catenin、PI3K、MAPK和JAK-STAT通路影响免疫反应,从而抑制肿瘤或促进肿瘤。总体而言,SH3BP2在癌症生长和免疫调节中发挥关键作用,使其成为CRC治疗的有前景的靶点。需要进一步的实验验证来证明其诊断和治疗效力。

展开英文摘要原文

AIM: Colorectal cancer (CRC) is a widespread health issue that attains high mortality. The adaptor protein SH3BP2 amplification results in metabolic changes, oxidative stress, NK cell activity, and inflammation. The NK cells are capable of destroying tumor cells without prior activation, help prevent metastasis, and have prognostic value. Targeting SH3BP2 to regulate NK cell activity in the TME could enhance CRC-based immunotherapy. MATERIALS AND METHODS: The cancer hallmark tool helps in understanding SH3BP2 hallmark annotation. Utilizing the STRING tool and the KEGG pathway, protein functional enrichment and PPI networking were analyzed. TIMER 2.0 was used for immune cell infiltration correlation analysis, and UALCAN was used for CPTAC-based protein expression profiling. RESULTS AND CONCLUSIONS: The GEO (GSE9348) dataset showed SH3BP2 is upregulated in CRC (log2 fold change = 1.18). GEO, TCGA, and cBioPortal revealed SH3BP2 alterations in CRC cases, potentially aiding immune evasion. Mutations in SH3BP2 influence cancer growth, suppressing tumors or promoting them by activating NF- B and affecting immune responses through WNT/ -catenin, PI3K, MAPK, and JAK-STAT pathways. Overall, SH3BP2 plays a key role in cancer growth and immune regulation, making it a promising target for CRC therapy. Further experimental validation is needed to demonstrate its diagnostic and therapeutic potency.

论文信息

作者
Jothimani M、Muthusamy K
单位
Pharmacogenomics and CADD Lab, Department of Bioinformatics, Alagappa University, Karaikudi, India.India
期刊
Personalized medicine2026 Aug
原文标识
PubMed 42682184 · DOI 10.1080/17410541.2026.2723766